Amgen stock

AMGN · NASDAQ · USD

$465.67Change from previous close: −0.30%Absolute change: −$1.39

Close · November 13, 2026

Price history

+38.59% over the period

1 year: from $336.00 (November 13, 2025) to $465.67 (November 13, 2026), +38.59%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$465.67
October 30, 2026$466.01
September 30, 2026$421.51
August 31, 2026$429.88
July 31, 2026$385.16
June 30, 2026$362.12
May 29, 2026$336.79
April 30, 2026$346.25
March 31, 2026$351.85
February 27, 2026$388.16
January 30, 2026$341.88
December 31, 2025$327.31
November 28, 2025$345.46
November 13, 2025$336.00

At a glance

TickerLandia's take on Amgen

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$312.39
52-wk high$483.99

−3.79% from the 52-week high

Analysts · 34 analysts

Average target$431.81−7.27% vs. price

Buy 11 · Hold 18 · Sell 5 · Hold

TickerLandia Fingerprint: Amgen

Compared with similar companies: very strong momentum.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Amgen is pricier than in the past and cheaper than similar companies

On the latest fiscal year's earnings (2025), Amgen's P/E today is 32.7, above the median of its last 10 fiscal years (21.8; between 14.3 and 64.6 from 2016 to 2025). Amgen's P/E (trailing 12 months): 27.0, −36% against the median of a group of 10 similar companies (42.3).

P/E compared with its history

Compared with 10 similar companies

Amgen's metrics compared with similar companies
MetricAmgenPosition in the groupBand
P/E (trailing 12 months)27.0Low
Forward P/E18.6High
Operating margin34.1%Middle
ROE78.4%High
Debt/equity3.76High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Amgen. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$10.37B

Latest quarter · Q3 2026

Net income

$3.86B

Latest quarter · Q3 2026

Quarterly net margin

37.3%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$251.89B
P/E
27.0
EPS
$17.25
Volume
2.12M
Daily trading
€1.12B
Dividend yield
2.13%

How Amgen is changing

All results
  • Revenue grew 7.6% a year on average over the last 5 years

  • Operating margin fell from 36.3% to 24.7%

  • Profits turn into cash: free cash flow equal to 140% of net income

Returns

Amgen returns with dividends

$1,000 invested in Amgen 5 years ago, on November 15, 2021, would be worth $2,601 today with dividends reinvested: +160.15% in total, +21.10% per year. On price alone it would be $2,245 (+124.53%).

PeriodAmgenS&P 500$1,000 becomes
1 month+12.80%−3.12%$1,128
6 months+38.41%+1.58%$1,384
Year to date+42.27%+10.46%$1,423
1 year+42.42%+12.23%$1,424
3 years+91.04%+71.41%$1,910
5 years+160.15%+61.48%$2,601
10 years+325.41%+249.40%$4,254

Over the last 6 months it has done better than 76% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Amgen: technical analysis

Amgen is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is 2.7% below its highest close since January 2, 1990 ($478.48, November 4, 2026).

Trend
Upward
RSI (14 sessions)
62
Between 30 and 70
vs 200-session average
+22.22%

Support and resistance

Price areas where Amgen has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price$465.67
  3. Support$446.63−4.09%3 touches, last on November 6, 2026
  4. Support$395.10−15.15%3 touches, last on October 6, 2026
  5. Support$376.62−19.12%3 touches, last on September 16, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.51
Volatility (60 sessions, annualised)
33.8%
Largest fall in the last year
−16.57%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Amgen: seasonality

Average monthly price change over 37 years

+1.8%Jan+0.0%Feb+1.1%Mar−0.5%Apr+1.3%May+0.5%Jun+8.0%Jul+1.1%Aug+0.2%Sep+1.7%Oct+2.9%Nov+3.4%Dec

Over the last 37 years, the strongest month for Amgen has been July: +8.03% on average, positive in 32 years out of 37. The weakest has been April: −0.47% on average, positive in 15 years out of 37. November, the current month, has been positive in 24 years out of 36 (+2.90% on average).

Show chart data
MonthAverageMedianPositive years
January+1.81%+2.14%22 of 36
February+0.02%−0.29%18 of 37
March+1.09%+1.13%19 of 37
April−0.47%−1.08%15 of 37
May+1.30%−0.16%18 of 37
June+0.52%+0.62%19 of 37
July+8.03%+6.36%32 of 37
August+1.08%+1.28%23 of 37
September+0.23%−0.79%17 of 37
October+1.66%+2.72%21 of 37
November+2.90%+2.21%24 of 36
December+3.41%+1.28%22 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Amgen and its competitors

Amgen's largest business is human therapeutics, which it discovers, develops, manufactures and delivers worldwide. Its principal products cover inflammatory diseases such as rheumatoid arthritis and psoriasis, bone disorders including osteoporosis, cardiovascular risk reduction, and cancers such as multiple myeloma and colorectal cancer, with brands including Enbrel, Otezla, Prolia, Repatha and KYPROLIS.

Headquarters
Thousand Oaks, United States
Employees
31,500
Founded
1980
Chief executive
Robert Bradway
Amgen and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
AmgenAMGN$251.89B34.1%27.0+38.41%
Gilead SciencesGILD$208.48B38.2%—+26.33%
MerckMRK$364.26B35.2%147.8+30.24%
PfizerPFE$164.67B29.1%41.3+11.29%
Bristol-Myers SquibbBMY$129.66B32.4%14.1+12.48%
AbbVieABBV$521.5B36.6%50.6+41.50%

Same industry or related industries, similar size. Compare Amgen with its competitors · Full profile